| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Human Tumors Immunobiology [R. M., A. Mo., I. B., A. A.] and Tumor Immunotherapy [G. P.] Units, Departments of Pathology [A. P., C. L., F. R.], Surgery [A. B., C. B., A. Ma., M. S.] and Scientific Direction [N. C.], Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, 20133, Italy
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In this study we investigated whether the natural evolution of human melanoma may promote the development of T-cell-mediated antitumor immunity to self-epitopes expressed on neoplastic cells. The results indicated that progression from primary lesions (stages I and II) to metastatic disease is associated with activation of CD8+ T-cell-mediated immunity to self-MDAs at the systemic and, in a fraction of patients, at tumor levels. However, in tumor-invaded, but not in TFLNs from the same nodal basin, CD8+ T cells showed a precursor phenotype, or their maturation was skewed toward a preterminally differentiated state. Furthermore, CD8+ T lymphocytes intermingling with neoplastic cells were defective for expression of key proteins for CTL activity mediated by the granule exocytosis pathway (14) . These results have implications for understanding the natural evolution of human melanoma and for the design of immunotherapy protocols, and suggest a new mechanism of tumor escape.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Tetramers and Flow Cytometry.
PE-labeled tetramers of HLA-A*0201 containing peptides from Melan-A/Mart-1 (modified sequence 26–35: ELAGIGILTV; Refs. 16
, 17
), gp100 (154–162: KTWGQYWQV; 209–217: ITDQVPFSV; Ref. 18
), Tyrosinase (368–377: YMDGTMSQV; Ref. 19
), and Influenza Matrix (58–66: GILGFVFTL; Ref. 20
) were provided by the National Institute of Allergy and Infectious Diseases Tetramer Facility and NIH AIDS Research and Reference Reagent Program (Bethesda, MD). Tetramers of HLA-A*0201 containing MAGE-3271–279 (21)
and NY-ESO-1157–165 (22)
peptides were purchased from ProImmune, Ltd. (Oxford, United Kingdom). Two x 106 cells were stained for 15 min with PE-labeled tetramers at 37°C, then stained for 30 min on ice with other cell surface antibodies. Different combinations of the following mouse antihuman monoclonal antibodies were used: anti-CD8 coupled to PerCp or APC, FITC- or PE-anti-CD45RA or anti-CD45RO, PerCp- or PE-anti-CD3, FITC- or APC-anti-CD27 and anti-CD28 (Becton Dickinson, Milan, Italy). To detect CCR7, cells were stained with IgM anti-CCR7 (BD PharMingen, San Diego, CA), followed by biotin-conjugated rat-antimouse IgM and then by Cy-chrome-conjugated streptavidin (BD PharMingen). To detect intracellular perforin or granzyme B, cells were permeabilized with Cytofix/Cytoperm (BD PharMingen) and then stained with FITC anti-Perforin (BD PharMingen), or with PE-antigranzyme B (CLB, Amsterdam, the Netherlands) in the presence of Perm/Wash solution (BD PharMingen). Acquisition and analysis by four- or three-color flow cytometry was carried out by a dual-laser FACScalibur cytofluorimeter (Becton Dickinson) using the Cellquest software. Negative controls for tetramer staining included PBL from HLA-A*0201- healthy controls.
T-Cell Activation.
Lymphocytes from peripheral blood or TILN were cultured for 2 weeks with HLA-A*0201+ T2 cells either empty or loaded with 0.1, 1, or 10 µg/ml of Melan-A/Mart-127–35 peptide as described (9)
. Frequency of tetramer+ T cells in the CD8+ fraction was analyzed before and at the end of culture. The frequency of tetramer+ T cells found at the end of culture was plotted against the peptide concentration (in µM). The dose of antigen required to achieve a 2-fold increase in frequency, compared with the initial frequency of peptide-specific T cells, was then estimated by linear regression analysis.
Intracellular IFN-
Detection.
Lymphocytes from peripheral blood, TILN, or short-term T-cell cultures activated with peptide-loaded T2 cells were stained with PE-tetramers for 15 min at 37°C and then were stimulated in the presence of 2 µM Melan-A/Mart-126–35 or gp100209–217 peptides for 4–6 h. After the first hour GolgiStop (BD PharMingen) was added. Cell surface staining was then carried out with PerCp-anti-CD8, followed by cell permeabilization with Cytofix/Cytoperm and then by staining with APC anti-IFN- monoclonal antibody in the presence of Perm/Wash solution. Expression of IFN- was then analyzed by flow cytometry after imposing a double gating for CD8+ and tetramer+ T cells (12)
.
Immunohistochemistry.
Immunohistochemical analysis of consecutive sections from routinely formalin or Bouin’s fixed and paraffin-embedded specimens, or from frozen tissues, was performed as described (9)
. The following antibodies were used: anti Melan-A/Mart-1, (Novocastra Laboratories, Newcastle upon Tyne, United Kingdom), anti-gp-100 (Dako, Glostrup, Denmark), anti-CD3 (Novocastra), anti-CD8 (Dako), anti-CD45RO (Dako), anti-Perforin (BD PharMingen), anti-Granzyme B (Monosan, Uden, the Netherlands), anti-CCR7 (BD PharMingen), anti-GMP-17/TIA-1 (Beckman Coulter, Fullerton, CA), anti-Ki-67 (MIB-1 antibody; Immunotech, Marseille, France), anti-HLA-A2 (clone CR11.351; Ref. 23
), and anti-NY-ESO-1 (D8.38 antibody; Ref. 24
). Granzyme B+ and perforin+ lymphocytes in TILN were counted after acquiring digital images of 10 areas of tissue sections (at x400 on a Zeiss Axiovert 100 microscope), each including both lymph node tissue and tumor tissue. Images of the corresponding fields stained with anti-CD8 mAb in serial sections were used to count intratumoral and extratumoral CD8+ cells. Apoptosis was detected with the terminal deoxynucleotidyltransferase in situ apoptosis detection kit (Genzyme, Cambridge, MA) according to the manufacturer’s instructions.
Statistical Analysis.
The data sets of frequency of T cells recognized by each of the tetramers in PBL of donors and patients, as well as in TILN and TFLN of patients, were not distributed normally, as indicated by Kolmogorov-Smirnov statistics. A nonparametric statistical analysis (Kruskal-Wallis test) followed by Dunn’s multiple comparison test was used.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. The two subsets of patients (stage I+II versus III+IV) differed for the proportion of CD8+ T cells directed against all four of the MDA epitopes. gp100209–217- and Melan-A/Mart-126–35-specific T cells showed the most marked and significant increase in metastatic patients compared with stage I+II patients (Fig. 1A)
. In addition, we found a significant accumulation of MDA-specific T cells in 44 TILNs compared with PBLs of the same patients, but only for Melan-A/Mart-126–35-specific T cells (Fig. 1A)
, and not for gp100-, tyrosinase-, or influenza-matrix-specific T cells (data not shown). Frequency of T cells directed to all four of the MDA epitopes and to Influenza-Matrix58–66 peptide (20)
did not differ in TILN compared with TFLNs removed at the same time from the same nodal basin (Fig. 1A
; for Melan-A/Mart-1-specific T cells; data not shown).
|
, a trend not found in Flu-matrix-specific T cells (Fig. 1B)
, suggesting that Cytotoxic T lymphocyte precursor frequency in PBL is affected not only by clinical stage but even by actual tumor burden.
Antigen-specific CD8+ T Cells in TILN Show a Precursor or a Preterminally Differentiated Phenotype.
To characterize the maturation stages of CD8+ T cells in patients, we evaluated gp100209–217, Melan-A/Mart-126–35, and Flu-Matrix58–66-specific T cells in PBL, TILN, and TFLN of stage III metastatic patients for expression of CCR7 and of CD45RA. In PBL and in TFLN a predominant phenotype was not found, although the CCR7+ CD45RA- subset was the least represented in PBL (mean: 12–14% of the tetramer+ T cells). However, in both PBL and TFLN, all of the maturation stages were observed, including terminally differentiated CCR7- CD45RA+ cells (Table 1)
. In contrast, TILN split into two subsets: in 7 of 23 patients, gp100, Melan-A/Mart-1, and Flu-matrix-specific T cells showed a predominant CCR7- CD45RA- phenotype, a "preterminal" stage of differentiation, according to the model put forward by Champagne et al. (12)
. Interestingly, these 7 TILNs included all of the lesions with a very high (>1.5% of all CD8+ T cells) frequency of Melan-A/Mart-126–35-specific T cells (P < 0.001 for the association of phenotype with tetramer frequency in the two groups of lesions; see legend to Table 1
). In the remaining 16 TILNs, the tetramer+ T cells showed a predominant CCR7+ CD45RA+ precursor phenotype (Table 1)
. Furthermore, analysis of T cells directed to two tumor-restricted antigens (MAGE-3271–279 and NY-ESO-1157–165 peptides), in TILN and TFLN from the same panel of patients, indicated a predominant CCR7+ CD45RA+ precursor phenotype in nearly all instances (Table 2)
. Immunohistochemistry for NY-ESO-1 in TILN sections from the same patients indicated that 78% of the lesions expressed this antigen on <10% of the neoplastic tissue (data not shown), suggesting that the predominant precursor phenotype of NY-ESO-1-specific T cells may be related to defective tumor antigen expression in the neoplastic tissue.
|
|
) and less frequently in those with a predominant CCR7+ phenotype (group of 8 patients in Table 3
). Melan-A/Mart-1-specific T cells in TFLN were mainly CCR7+ and perforin-(Table 3)
. A similar CCR7+ perforin- phenotype was expressed even by the MAGE-3-specific T cells in both TILN and TFLN (Table 3)
.
|
. In TILNs where MDA-specific T lymphocytes showed a predominant CCR7- CD45RA- phenotype (as in patients #3, #4, and #5), these cells expressed mostly the early (CD27+ CD28+) and intermediate (CD27+, CD28-) stages of differentiation, but not the CD27- CD28- phenotype associated with the "late" maturation stage (Ref. 13
; Fig. 2
). The CD27/CD28 phenotype of tetramer+ T cells was in agreement with that shown by the bulk CD3+ CD8+ T-cell population in the two groups of patients (Fig. 2)
and with the phenotype for these markers expressed by Flu-Matrix58–66-specific T cells in TILN (data not shown).
|
Preterminally Differentiated Memory CD8+ T Cells in TILN Are Not Functionally Impaired.
To evaluate whether the preterminally differentiated T cells from TILN were functionally competent, tetramer+ T cells directed to Melan-A/Mart-126–35 or gp100209–217 and showing a predominant (>80%) CCR7- CD45RA- phenotype were tested for IFN- production in response to the specific peptide. In such T cells, staining for intracellular IFN-, after peptide-stimulation, was detected not only after preactivation for 1 week with peptide-loaded APCs but even in freshly isolated lymphocytes (Fig. 3
; representative of 6 patients investigated). The latter response was not detected when we tested TILN-derived Melan-A/Mart-1-specific T cells with a predominant CCR7+ CD45RA+ phenotype (data not shown). Similarly, Melan-A/Mart-1- or gp100-specific T cells containing <20% of CCR7- CD45RA- cells, and isolated from PBLs, stained for peptide-induced intracellular IFN- only after preactivation with peptide-loaded APCs (Fig. 3)
.
|
. Linear regression analysis of dose-response curves at peptide doses between 0.1 and 10 µM indicated that CCR7- CD45RA-- Melan-A/Mart-126–35-specific T cells from TILN required a peptide dose 
46 times lower than Melan-A/Mart-1-specific T cells from PBLs (P < 0.01) to achieve the same outgrowth (2-fold increase compared with initial frequency; Fig. 5
) in agreement with the concept that antigen-experienced T cells can express increased clonal expansion at low antigen doses compared with naive T cells (25)
.
|
|
). In contrast, of 44 TILNs investigated, 33 (75%) contained infiltrating CD3+ CD8+ cells (Fig. 6
; data not shown). These 33 lesions included the TILNs from the 7 patients with the highest frequency of T cells to Melan-A/Mart-1 and with a skewed CCR7- CD45RA- phenotype. In agreement, in the same lesions we found that CD8+ cells infiltrating the neoplastic tissue of TILN lacked CCR7 and expressed CD45RO, the reciprocal isoform of CD45RA (Fig. 6)
. Thus, even by immunohistochemistry, we did not find evidence for terminally differentiated (i.e., CCR7- CD45RO-/RA+) CD8+ T cells infiltrating the metastatic lesions.
|
. In particular, in these patients, we found perforin and granzyme B expressed on a higher fraction of the CD8+ lymphocytes located in the residual lymph node tissue surrounding the invading tumor, with remarkably fewer positive lymphocytes among those intermingling with the neoplastic tissue (Fig. 7
and Fig. 8
). Such incomplete maturation and defective expression of cytotoxic factors in the infiltrating CD8+ T cells was not associated with lack of HLA-A2 molecules or MDA on the neoplastic cells. In fact, in a panel of several TILNs the highest frequency of expression of HLA-A2, Melan-A/Mart-1, and gp100 on the neoplastic cells was found in the lesions from the 7 patients with the skewed CCR7- CD45RA- phenotype of CD8+ T cells (Fig. 9)
. Finally, in all of the patients in the panel of TILNs, analysis of invaded lymph node sections for morphological evidence of tumor necrosis and/or regression, or apoptosis (by TUNEL staining), failed to show evidence for tumor destruction in all of the lesions (representative results from 3 patients shown in Fig. 10
), suggesting that incomplete CD8+ T-cell maturation and reduced expression of cytotoxic factors in CD8+ T cells may impair tumor cell destruction in the invaded lymph nodes.
|
|
|
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Taken together our results suggest that the immune system of melanoma patients reacts to tumor growth by recognizing neoplastic cells in the invaded lymph nodes and/or changes in the level of MDA load, occurring at time of progression to metastatic disease. This possibility is in agreement with findings obtained in murine models (7) , where the presence of T cells intermingling with the tumor nodules in TILN has been shown to represent a relevant factor for the activation of immunity at tumor site.
Differential epitope immunogenicity appears to play a significant role in T-cell accumulation at tumor site, even in the response to different epitopes of the MDA class. In fact, only Melan-A/Mart-126–35-specific T cells, of the four MDAs investigated, showed a significant expansion in TILNs compared with PBLs of metastatic patients. This finding cannot be explained solely on the basis of the principle of degeneracy of antigen recognition, i.e., the existence of largely cross-reactive subsets of naive CD8+ T cells against this epitope (29)
. In fact, in patients with the highest frequency of T cells to this peptide, the T cells in TILN did not express a CCR7+ CD45RA+ "naive" phenotype and recognized the cognate antigen in a functional assay (IFN- production). Thus, we favor an alternative explanation based on the finding that Melan-A/Mart-126–35 CTL epitope is poorly generated by the immunoproteasome of mature dendritic cells (30)
. On the basis of the proposed role of professional APCs in maintaining tolerance to self-antigens (10
, 31)
, then epitopes poorly presented by such cells may not induce tolerance (32)
. Therefore, immunogenicity of Melan-A/Mart-126–35 may at least in part depend on direct antigen presentation at tumor site, after Melan-A/Mart-1 protein processing through the constitutive proteasome of neoplastic cells.
The phenotypic and functional characteristics of the MDA-specific T-cell population found in TILNs of a group of metastatic patients are in agreement with a preterminally differentiated state, according to the model by Champagne et al. (12) . However, this partial maturation of antitumor CD8+ T cells took place only in a fraction of TILNs, as in the majority of lesions T cells directed to MDA or to tumor-restricted epitopes (such as MAGE-3 and NY-ESO-1 peptides) showed a predominant precursor phenotype (CCR7+ CD45RA+ CD27+ CD28+) and lacked of perforin. Furthermore, comparison of maturation phenotype of antigen-specific T cells in TILNs, by the CCR7/CD45RA and CD27/CD28 models, provided concordant evidence for the almost complete absence of T cells defined as "terminally differentiated" (i.e., CCR7- CD45RA+), or in "late stage" of differentiation (i.e., CD27- CD28-), even in those patients where a partial maturation of MDA-specific T cells took place.
We observed that tumor-infiltrating lymphocytes in TILN lacked CD4+ cells, although these cells were present in the residual lymph node tissue not invaded by neoplastic cells. This suggests that lack of CD4 T-cell help in the tumor tissue may prevent terminal differentiation of the infiltrating memory CD8+ T cells, as suggested by Champagne et al. (12) . However, the impact of the cytokine "milieu" of the tumor microenvironment should also be considered. For example, inadequate production, at tumor site, of cytokines such as IL-15 and IL-7, which play a major role in generation and homeostasis of memory CD8+ T cells (33) , could prevent efficient T-cell maturation.
Furthermore, by immunohistochemistry, in TILNs, we found that CD8+ cells expressed a marker of cytolytic granules (TIA-1/GMP-17; Ref. 26 ), whereas perforin and granzyme B, two key proteins for CTL activity mediated by the granule exocytosis pathway (14) , were expressed only in a fraction of these lymphocytes, and mainly in cells that surrounded the tumor, rather than in those that infiltrated it. These results are consistent with the hypothesis of incomplete maturation of the CD8+ T lymphocytes that infiltrate the tumor. Furthermore, the expression of HLA-A2 and MDA on most neoplastic cells, in the lesions of patients with a predominant CCR7- CD45RA- CD27+ CD28- phenotype of the tetramer+ T cells, suggests that lack of terminally differentiated CD8+ T cells may not be attributable simply to loss of MHC and antigen expression on the tumor. On the other hand, the expression of HLA-A2 on the cell surface and the presence of MDA proteins in the cytoplasm, detected by immunohistochemistry, do not rule out the possibility that the neoplastic cells lack the specific HLA-A2-peptide complexes needed to promote differentiation of antigen-specific CD8+ T cells. An alternative explanation for the low expression of cytotoxic factors in the CD8+ cells in TILN is degranulation, but this is not supported by the results on TIA-1/GMP-17 staining. In fact, no membrane staining for TIA-1/GMP-17 was detected, as it occurs when degranulation takes place (26) , as the staining for this marker was always granular and associated with the cytoplasm. In addition, we never observed perforin or granzyme B expression associated with neoplastic cells, as it has been described in nodal metastasis of breast and lung tumors (34) , where it indicates degranulation from the infiltrating lymphocytes and transfer of cytotoxic factors to neoplastic cells.
The markedly reduced expression of perforin and granzyme B, among infiltrating CD8+ T cells, suggests that tumor cell destruction by infiltrating T cells is markedly impaired even in those lesions where partial differentiation of CD8+ T cells directed to MDA epitopes took place. In agreement with this possibility, by TUNEL staining for apoptosis, or by morphological analysis for tumor necrosis and/or regression, we did not find evidence for tumor cell destruction in the TILN. Taken together, these findings have implications not only for the understanding of the natural evolution of human melanoma, but even for the design of immune intervention approaches to therapy. The activation and/or boosting of T cell-mediated immune response to melanoma antigens, through vaccines, may need to be coupled with efficient means to promote efficient CD8+ T-cell maturation in the tumor tissue. To this end the use of adjuvants that may promote CTL maturation, such as cytokines as IL-2 and IL-15, may lead to increased efficacy of melanoma vaccines.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported in part by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC; Milan), the Ministry of Health (Rome), and Consiglio Nazionale delle Ricerche (CNR; Rome). 
2 To whom requests for reprints should be addressed, at Human Tumors Immunobiology Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. Phone: 39-0223902817; Fax: 39-0223902630; E-mail: andrea.anichini{at}istitutotumori.mi.it
3 The abbreviations used are: MDA, melanocyte differentiation antigen; AJCC, American Joint Committee on Cancer; APC, antigen-presenting cell; CTL, cytotoxic T lymphocyte; PBL, peripheral blood lymphocyte; TFLN, tumor-free lymph node; TILN, tumor-invaded lymph node; PE, phycoerythrin; IL, interleukin; TUNEL, terminal deoxynucleotidyltransferase-mediated nick end labeling.
Received 11/ 4/02. Accepted 3/13/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (Lond.), 410: 1107-1111, 2001.[Medline]
This article has been cited by other articles:
|
|
 |
|
  R. Mortarini, C. Vegetti, A. Molla, F. Arienti, F. Ravagnani, A. Maurichi, R. Patuzzo, M. Santinami, and A. Anichini Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage Clin. Cancer Res., June 15, 2009; 15(12): 4085 - 4094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Harlin, Y. Meng, A. C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, M. McKee, and T. F. Gajewski Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment Cancer Res., April 1, 2009; 69(7): 3077 - 3085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Casado, O. DelaRosa, G. Pawelec, E. Peralbo, E. Duran, F. Barahona, R. Solana, and R. Tarazona Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells Int. Immunol., January 1, 2009; 21(1): 53 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Maccalli, V. Di Cristanziano, V. Fodale, D. Corsi, G. D'Agostino, V. Petrangeli, L. Laurenti, S. Guida, A. Mazzocchi, F. Arienti, et al. Induction of Both CD8+ and CD4+ T-Cell-Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1 Clin. Cancer Res., November 15, 2008; 14(22): 7292 - 7303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Walker, D. Haley, U. Petrausch, K. Floyd, W. Miller, N. Sanjuan, G. Alvord, B. A. Fox, and W. J. Urba Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization Clin. Cancer Res., August 15, 2008; 14(16): 5270 - 5283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Savage, K. Vosseller, C. Kang, K. Larimore, E. Riedel, K. Wojnoonski, A. A. Jungbluth, and J. P. Allison Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8+ T Lymphocytes Science, January 11, 2008; 319(5860): 215 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lengagne, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.-G. Guillet, V. H. Engelhard, M.-F. Avril, J.-P. Abastado, and A. Prevost-Blondel Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases J. Immunol., January 1, 2008; 180(1): 130 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini, C. Castelli, and G. Parmiani NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients Clin. Cancer Res., December 15, 2007; 13(24): 7459 - 7468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Inokuma, C. dela Rosa, C. Schmitt, P. Haaland, J. Siebert, D. Petry, M. Tang, M. A. Suni, S. A. Ghanekar, D. Gladding, et al. Functional T Cell Responses to Tumor Antigens in Breast Cancer Patients Have a Distinct Phenotype and Cytokine Signature J. Immunol., August 15, 2007; 179(4): 2627 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor J. Immunol., June 1, 2007; 178(11): 6752 - 6760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Pupa, S. Giuffre, F. Castiglioni, L. Bertola, M. Cantu, I. Bongarzone, P. Baldassari, R. Mortarini, W. S. Argraves, A. Anichini, et al. Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1 Cancer Res., May 1, 2007; 67(9): 4271 - 4277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials J. Immunol., February 15, 2007; 178(4): 1975 - 1979. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bioley, C. Jandus, S. Tuyaerts, D. Rimoldi, W. W. Kwok, D. E. Speiser, J.-M. Tiercy, K. Thielemans, J.-C. Cerottini, and P. Romero Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers J. Immunol., November 15, 2006; 177(10): 6769 - 6779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. A. Doyle, J. Zhou, M. J. Wolff, B. P. Harvey, R. M. Roman, R. J. Gee, R. A. Koski, and M. J. Mamula Isoaspartyl Post-translational Modification Triggers Anti-tumor T and B Lymphocyte Immunity J. Biol. Chem., October 27, 2006; 281(43): 32676 - 32683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Brown, C. Blank, J. Kline, A. K. Kacha, and T. F. Gajewski Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection J. Immunol., October 1, 2006; 177(7): 4521 - 4529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Appay, C. Jandus, V. Voelter, S. Reynard, S. E. Coupland, D. Rimoldi, D. Lienard, P. Guillaume, A. M. Krieg, J.-C. Cerottini, et al. New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site J. Immunol., August 1, 2006; 177(3): 1670 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Anichini, R. Mortarini, D. Nonaka, A. Molla, C. Vegetti, E. Montaldi, X. Wang, and S. Ferrone Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients. Cancer Res., June 15, 2006; 66(12): 6405 - 6411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J.C.L.M. Vuylsteke, B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, P. G.J.T.B. Wijnands, J. B.A.G. Haanen, R. J. Scheper, and T. D. de Gruijl Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content. Clin. Cancer Res., May 1, 2006; 12(9): 2826 - 2833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Gajewski Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin. Cancer Res., April 1, 2006; 12(7): 2326s - 2330s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Keilholz, P. Martus, and C. Scheibenbogen Immune monitoring of T-cell responses in cancer vaccine development. Clin. Cancer Res., April 1, 2006; 12(7): 2346s - 2352s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liu, S. A. Caldwell, K. M. Greeneltch, D. Yang, and S. I. Abrams CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape J. Immunol., March 15, 2006; 176(6): 3374 - 3382. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gillmore, S.-A. Xue, A. Holler, J. Kaeda, D. Hadjiminas, V. Healy, R. Dina, S. C. Parry, I. Bellantuono, Y. Ghani, et al. Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer Clin. Cancer Res., January 1, 2006; 12(1): 34 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Dranoff The Therapeutic Implications of Intratumoral Regulatory T Cells Clin. Cancer Res., December 1, 2005; 11(23): 8226 - 8229. [Full Text] [PDF]
|
|
|
|
|
|
G. Parmiani, C. Castelli, and L. Rivoltini Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients Clin. Cancer Res., November 1, 2005; 11(21): 7587 - 7588. [Full Text] [PDF]
|
|
|
|
|
|
A. A. Lugade, J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor J. Immunol., June 15, 2005; 174(12): 7516 - 7523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico, V. Bronte, R. Longhi, M. P. Colombo, G. Dougan, and M. Rescigno Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells Cancer Res., May 1, 2005; 65(9): 3920 - 3927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mortarini, A. Scarito, D. Nonaka, M. Zanon, I. Bersani, E. Montaldi, E. Pennacchioli, R. Patuzzo, M. Santinami, and A. Anichini Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles Cancer Res., April 15, 2005; 65(8): 3428 - 3436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawano, C. L. Efferson, G. E. Peoples, D. Carter, N. Tsuda, J. L. Murray, and C. G. Ioannides Sensitivity of Undifferentiated, High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor Antigen Determines Their Differentiation or Death Cancer Res., April 1, 2005; 65(7): 2930 - 2937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Zhou, D. Y. Jun, A. M. Thomas, X. Huang, L.-Q. Huang, J. Mautner, W. Mo, P. F. Robbins, D. M. Pardoll, and E. M. Jaffee Diverse CD8+ T-Cell Responses to Renal Cell Carcinoma Antigens in Patients Treated with an Autologous Granulocyte-Macrophage Colony-Stimulating Factor Gene-Transduced Renal Tumor Cell Vaccine Cancer Res., February 1, 2005; 65(3): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sensi, G. Nicolini, M. Zanon, C. Colombo, A. Molla, I. Bersani, R. Lupetti, G. Parmiani, and A. Anichini Immunogenicity without Immunoselection: A Mutant but Functional Antioxidant Enzyme Retained in a Human Metastatic Melanoma and Targeted by CD8+ T Cells with a Memory Phenotype Cancer Res., January 15, 2005; 65(2): 632 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-J. Kim, T. M. Stringfield, Y. Chen, and H. E. Broxmeyer Modulation of cord blood CD8+ T-cell effector differentiation by TGF-{beta}1 and 4-1BB costimulation Blood, January 1, 2005; 105(1): 274 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Meidenbauer, A. Zippelius, M. J. Pittet, M. Laumer, S. Vogl, J. Heymann, M. Rehli, B. Seliger, S. Schwarz, F.-A. L. Gal, et al. High Frequency of Functionally Active Melan-A-Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma Cancer Res., September 1, 2004; 64(17): 6319 - 6326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al. Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zippelius, P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al. Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance Cancer Res., April 15, 2004; 64(8): 2865 - 2873. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
, matched PBL and TILN samples; 
, unmatched TILN samples.
) Melan-A/Mart-1-specific T cells in the metastatic lymph nodes.